YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas

Catherine L. Nutt, Rebecca Betensky, Melissa A. Brower, Tracy T. Batchelor, David N. Louis, Anat O. Stemmer-Rachamimov

Research output: Contribution to journalArticle

Abstract

Purpose and Experimental Design: In modern neurooncology, no variable affects therapeutic decisions and prognostic estimation more than tumor classification. We showed recently that class prediction models, based on gene expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than standard pathology. In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas. Results and Conclusions: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas. Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix. Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+. YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas. Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.

Original languageEnglish (US)
Pages (from-to)2258-2264
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number6
DOIs
StatePublished - Mar 15 2005

Fingerprint

Oligodendroglioma
Glioma
Glioblastoma
Staining and Labeling
Glial Fibrillary Acidic Protein
Extracellular Matrix
Neoplasms
Immunohistochemistry
Transcriptome
Research Design
Coloring Agents
Pathology
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nutt, C. L., Betensky, R., Brower, M. A., Batchelor, T. T., Louis, D. N., & Stemmer-Rachamimov, A. O. (2005). YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clinical Cancer Research, 11(6), 2258-2264. https://doi.org/10.1158/1078-0432.CCR-04-1601

YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. / Nutt, Catherine L.; Betensky, Rebecca; Brower, Melissa A.; Batchelor, Tracy T.; Louis, David N.; Stemmer-Rachamimov, Anat O.

In: Clinical Cancer Research, Vol. 11, No. 6, 15.03.2005, p. 2258-2264.

Research output: Contribution to journalArticle

Nutt, CL, Betensky, R, Brower, MA, Batchelor, TT, Louis, DN & Stemmer-Rachamimov, AO 2005, 'YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas', Clinical Cancer Research, vol. 11, no. 6, pp. 2258-2264. https://doi.org/10.1158/1078-0432.CCR-04-1601
Nutt, Catherine L. ; Betensky, Rebecca ; Brower, Melissa A. ; Batchelor, Tracy T. ; Louis, David N. ; Stemmer-Rachamimov, Anat O. / YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 6. pp. 2258-2264.
@article{023aeb3eacdd40e388f6260c1cb8564b,
title = "YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas",
abstract = "Purpose and Experimental Design: In modern neurooncology, no variable affects therapeutic decisions and prognostic estimation more than tumor classification. We showed recently that class prediction models, based on gene expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than standard pathology. In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas. Results and Conclusions: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas. Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix. Tumor cell staining intensity was also markedly different: 84{\%} of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76{\%} of anaplastic oligodendrogliomas either did not stain or stained at only 1+. YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas. Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.",
author = "Nutt, {Catherine L.} and Rebecca Betensky and Brower, {Melissa A.} and Batchelor, {Tracy T.} and Louis, {David N.} and Stemmer-Rachamimov, {Anat O.}",
year = "2005",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1601",
language = "English (US)",
volume = "11",
pages = "2258--2264",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas

AU - Nutt, Catherine L.

AU - Betensky, Rebecca

AU - Brower, Melissa A.

AU - Batchelor, Tracy T.

AU - Louis, David N.

AU - Stemmer-Rachamimov, Anat O.

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Purpose and Experimental Design: In modern neurooncology, no variable affects therapeutic decisions and prognostic estimation more than tumor classification. We showed recently that class prediction models, based on gene expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than standard pathology. In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas. Results and Conclusions: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas. Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix. Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+. YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas. Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.

AB - Purpose and Experimental Design: In modern neurooncology, no variable affects therapeutic decisions and prognostic estimation more than tumor classification. We showed recently that class prediction models, based on gene expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than standard pathology. In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas. Results and Conclusions: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas. Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix. Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+. YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas. Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.

UR - http://www.scopus.com/inward/record.url?scp=16844376506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844376506&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1601

DO - 10.1158/1078-0432.CCR-04-1601

M3 - Article

C2 - 15788675

AN - SCOPUS:16844376506

VL - 11

SP - 2258

EP - 2264

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -